Aktien Sensor

Quest Diagnostics’ stock price has declined 1.8% following the release of its latest earnings report, affecting its market value of approximately $19.7 billion.

Quest Diagnostics has announced a quarterly cash dividend and will present at the William Blair 45th Annual Growth Stock Conference in June.

Quest Diagnostics is poised for continued growth, driven by advancements in time-series data processing and a strong commitment to innovation, with its stock value expected to increase further.

Quest Diagnostics has introduced AD-Detect, a blood test that boasts over 90% accuracy in diagnosing Alzheimer’s disease, potentially revolutionizing the way the condition is diagnosed and managed.

Quest Diagnostics has launched a new FDA-cleared HPV self-collection solution, but experts warn that it may not be enough to address the alarming decline in cervical cancer screening rates in the US.

Quest Diagnostics is set to release its Q1 2025 earnings on April 22, 2025, with investors anticipating the company’s continued growth and innovation in the healthcare industry.

Quest Diagnostics’ stock performance has drawn attention from investors and analysts, with its current price of $167.33 USD and valuation metrics sparking interest in its future trajectory.

Quest Diagnostics’ stock price has been volatile, with a 52-week high of $178.87 and a 52-week low of $125.42, leaving investors wondering what’s next for the company.

Quest Diagnostics partners with Google Cloud, while NVIDIA introduces new AI solutions, potentially boosting stock performance for companies involved in the partnerships.

Quest Diagnostics reaffirms its 2025 guidance, projecting steady revenue and earnings growth, with a long-term outlook of 4-5% revenue and 7-9% EPS growth beyond 2025.